Screen readers: Two navigational links to follow.Skip to site navigation.Skip to page content.
The University of Iowa News Services
The University of Iowa News Services Home News Releases UI in the News Subscribe to UI News Contact Us

University of Iowa News Release


Oct. 9, 2008

Overactive bladder study seeks men age 40 and older

Men age 40 and older with overactive bladder symptoms that have not been controlled by alpha-blocker treatment alone are invited to participate in a University of Iowa research study.

The study focuses on whether an investigational medicine can reduce urinary frequency, urgency and/or incontinence when added to existing alpha-blocker treatment. The study will compare the combination of active investigational medication and prescribed alpha-blocker to the combination of placebo and prescribed alpha-blocker.

Men with a history of interstitial cystitis or prostate cancer are not eligible to participate.

The study will involve approximately five visits to UI Hospitals and Clinics over 13 weeks. Participants will randomly be assigned to take the active study medication or the placebo in addition to their currently prescribed alpha-blocker. All participants will be asked to keep a voiding diary and complete several quality-of-life questionnaires about bladder health.

Study drug and any related tests will be provided at no cost. Compensation for clinic visits and parking is also available.

The UI is one of approximately 180 sites worldwide taking part in the study. Elizabeth Takacs, M.D., clinical assistant professor of urology, is the lead investigator for the UI site.

For more information about participating in this study contact the study coordinator Mary Eno at 319-384-9265 or

STORY SOURCE: University of Iowa Health Science Relations, 5137 Westlawn, Iowa City, Iowa, 52242

MEDIA CONTACT: [The following contact information is for reporters only; please use the contact information provided in the last paragraph of the news release to reach the study coordinators.] Becky Soglin, UI Health Science Relations, 319-335-6660,